Full Year 2023 Investor Presentation

82 Investor presentation Full year 2023 Rare disease sales decreased by 15%, driven by reduction in manufacturing output NovoSevenⓇ and NorditropinⓇ DKK billion account for ~66% of Rare disease sales DKK billion Global Rare disease franchise 25 25 1% 4% 1% -15% 1% 4% 1% -15% 20 20 20 15 10 5 0 2020 2021 2022 2023 NovoSevenⓇ Primarily NorditropinⓇ Other haemophilia products¹ Other Rare disease Growth at CER 1Other haemophilia products primarily consists of Vagifem® and ActivelleⓇ CER: Constant exchange rates Note: Company reported sales 8 15 7 7 8 10 12 12 13 5 9 2020 2021 2022 2023 IO NAO Growth at CER Novo NordiskⓇ

View entire presentation